Beleave Inc. (CSE:BE) (“Beleave” or the “Company”) is pleased to announce that its wholly owned subsidiary Beleave Kannabis Corp. has received its approval and provider number to service those who have qualified for cannabis coverage through Medavie Blue Cross including the Canadian veteran community.  With over 1,000,000 card holders Medavie Blue Cross is one of Canada’s leading Blue Cross plans and although each card holder’s benefits may differ, cannabis coverage is available to patients approved by Blue Cross.

Medavie Blue Cross administers to various government sponsored health programs on behalf of the provincial and federal governments which include Veterans Affairs Canada, an important segment of Beleave’s patient acquisition strategy.


“We aim to help provide ease of access to those with Blue Cross coverage allowing patients to cut a multitude of steps typically needed to make a claim,” commented Beleave CEO Andrew Wnek. “Our team is ready to accept new patients and are confident in our ability to provide the highest quality service to all patients including our country’s respected servicemen and women.”

The Company’s Medi Green Clinic network plans to host multiple location information sessions for veterans on an ongoing basis.  These initiatives will be rolled out by the Company’s growing Veteran Affairs and Community outreach division.  To stay informed please join the company mailing list at www.beleave.com.

About Medavie Blue Cross
Medavie is a non-profit Canadian Medical care insurance company headquartered in Moncton, New Brunswick.  The Company was named one of Canada’s Top 100 Employers by Maclean’s magazine and is the only non-profit medical insurance organization in Canada to receive this honour.

About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.

Click here to connect with Beleave Inc. (CSE:BE) for an Investor Presentation.

Source: www.newswire.ca

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less